katrin Sjoquist — ASN Events

katrin Sjoquist — ASN Events

, ,

Presentations this author is a contributor to:

Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial (#268)

Lorraine Chantrill

Second-line chemotherapy in advanced biliary tract cancer: A retrospective series (#346)

Baseline predictors of early treatment failure in patients with Platinum Resistant/ Refractory (PRR) and Potentially Platinum Sensitive (PPS) recurrent ovarian cancer (ROC) receiving ≥3 lines of chemotherapy- The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) (#203)

Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)? Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). (#167)

Best of the Best Posters - Survivorship & Supportive care

PARAGON- An ANZGOG Phase 2 study of anastrazole in asymptomatic women with estrogen (ER)/ progesterone (PR) positive ovarian cancer with a CA125 progression after first line treatment. (#186)